On February 3, 2020 Calidi Biotherapeutics, Inc., a clinical‐stage immuno-oncology company at the forefront of cell-based oncolytic virus immunotherapies for cancer, reported the acceptance of an abstract for presentation at the ASCO (Free ASCO Whitepaper)-SITC Clinical Immuno-Oncology Symposium, which is being held February 6 to February 8, 2020, at the Rosen Shingle Creek Resort in Orlando, Florida (Press release, Calidi Biotherapeutics, FEB 3, 2020, View Source [SID1234553786]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We look forward to sharing our data evidencing the ability of Calidi’s proprietary cell-based delivery platform to address a major obstacle in oncolytic virotherapy – the quick elimination of oncolytic viruses by the patient’s immune system," said Boris Minev, MD, President, Medical and Scientific Affairs, Calidi Biotherapeutics. "Calidi’s platform not only protects, amplifies, and delivers the oncolytic viruses, but it also modifies the tumor microenvironment and activates the immune system to actively seek, and destroy distant tumor sites."

ASCO-SITC Presentation Details Are As Follows:

Board C3
Abstract 21: A cell-based platform to potentiate oncolytic virus therapies.

Date: Thursday, February 6, from 11:30 AM – 1:00 PM and 6:00 PM – 7:00 PM
Location: Rosen Shingle Creek, Orlando, FL
Key Words: oncolytic virus, cancer, cancer therapies, cell-based delivery platform